IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs

Zacks
Открыть на Zacks
IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs

Iovance Biotherapeutics IOVA incurred a third-quarter 2026 loss of 5 cents per share, narrower than the Zacks Consensus Estimate of a loss of 9 cents. In the year-ago quarter, the company reported a loss of 25 cents.

Revenues increased 80.1% year over year to $121.5 million, topping the Zacks Consensus Estimate of $117.7 million. Robust Amtagvi demand fueled the beat, with quarterly U.S. sales of the melanoma cell therapy surpassing $100 million for the first time.

Shares of Iovance fell 11% on Thursday despite the better-than-expected results. The decline may have partly reflected broader market weakness amid investor uncertainty following the Democrats’ victories in the U.S. midterm elections.

Year to date, the stock has surged roughly 184% compared with the industry’s nearly 12% growth.

Zacks Investment Research
Image Source: Zacks Investment Research

IOVA's Amtagvi Sales Top Estimates

Amtagvi, its tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, recorded approximately $102 million in U.S. sales. The total was up 77% from the year-ago quarter and 12% sequentially, beating both the Zacks Consensus Estimate and our model estimate of $95 million.

Proleukin, the IL-2 therapy used alongside Amtagvi, generated about $20 million globally. Sales were below the $22 million projected by both the consensus estimate and our model but more than doubled sequentially as wholesaler purchasing realigned with Amtagvi demand. Management said Proleukin purchases now broadly track expected patient use.

Iovance Raises Gross Margin as R&D Spending Falls

Iovance's gross margin, excluding depreciation and amortization, climbed to approximately 60% from 56% in the preceding quarter. This marked the second straight quarterly record, supported by higher product volume, manufacturing efficiencies and cost optimization.

Research and development expenses fell 34.4% year over year to $49.3 million, marking a fifth consecutive quarterly decline. Selling, general and administrative costs rose 11.6% year over year to $38.6 million, although they remained broadly steady compared with the previous quarter.

IOVA Reaffirms Its 2026 Revenue Outlook

Iovance reaffirmed its recently updated full-year 2026 revenue guidance of $410 million to $420 million. Revenues totaled $292.2 million during the first nine months, with management expecting additional sequential growth in the fourth quarter.

Management expects gross margin to improve further, excluding occasional one-time items. The company held roughly $382 million in cash, cash equivalents, short-term investments and restricted cash as of Sept. 30, 2026, which it expects to fund operations well into 2029.

Iovance Extends Amtagvi's Commercial Reach

More than 1,000 patients have received commercial Amtagvi since launch. The network exceeds 100 authorized treatment centers across the United States, Canada and Australia, with at least 110 expected to be active by year-end. Community sites account for more than one-third of existing centers.

The manufacturing turnaround is 30 days or less for most lots. Canada and Australia have approved Amtagvi, with reimbursement discussions underway. Iovance anticipates potential approvals in the U.K. and Switzerland in the first quarter of 2027. A Brazilian regulatory filing and a European Union resubmission are planned for 2027.

IOVA Nears Lung Cancer Filing

Iovance continues to advance Amtagvi in non-small cell lung cancer (NSCLC), with encouraging results from the phase II IOV-LUN-202 study. The company recently reported an objective response rate (ORR) of 24.6% among 69 patients with previously treated non-squamous metastatic NSCLC, including two unconfirmed responses. The results compare favorably with the 12.8% response rate reported for the chemotherapy drug docetaxel in a separate study.

Management also highlighted response durability, with approximately half of responding patients still showing responses. The safety profile improved after introducing a reduced-dose lymphodepletion regimen without compromising the observed efficacy. Iovance is completing enrollment in the study's first two cohorts, targeting approximately 80 patients. The company plans to seek expanded approval through a supplemental biologics license application (sBLA) in 2027.

Separately, Iovance identified a biomarker-selected subgroup of patients with lung cancer who achieved a substantially higher ORR of 59.1%. These findings prompted the launch of POSITILITY, a new registrational-intent cohort targeting 80 patients, with enrollment expected to begin in November 2026. The company also plans to initiate OPTILISM in 2027 to evaluate lifileucel in biomarker-selected patients with previously untreated metastatic NSCLC, potentially expanding its use into the frontline setting.

Beyond lung cancer, Iovance is evaluating Amtagvi across separate mid-stage studies for endometrial cancer and soft tissue sarcomas. It intends to submit an sBLA in the endometrial cancer indication in 2028 or 2029.

The company is also evaluating Amtagvi in combination with Merck’s MRK Keytruda in the phase III TILVANCE-301 study as a potential treatment for frontline advanced melanoma. This study will also serve as a confirmatory study for the therapy in the currently approved indication.

IOVA’s Zacks Rank

Iovance currently carries a Zacks Rank #2 (Buy).

Iovance Biotherapeutics, Inc. Price

Iovance Biotherapeutics, Inc. Price

 

Iovance Biotherapeutics, Inc. price | Iovance Biotherapeutics, Inc. Quote

Other Key Picks Among Biotech Stocks

Some other top-ranked stocks include TG Therapeutics TGTX and Amneal Pharmaceuticals AMRX. While TGTX sports a Zacks Rank #1 (Strong Buy), AMRX carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 30 days, earnings per share (EPS) estimates for TG Therapeutics have risen from 92 cents to 94 cents for 2026. Over the same period, estimates for 2027 EPS have increased from $2.65 to $2.66. TGTX’s shares have risen nearly 95% year to date.

TG Therapeutics’ earnings missed estimates in three of the trailing four quarters and beat in the remaining one, with an average surprise of 184.65%.

Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.03 to $1.04 for 2026. Over the same period, estimates for 2027 EPS have risen from $1.16 to $1.19. AMRX’s shares have climbed more than 54% year-to-date.

Amneal Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 27.21%.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Iovance Biotherapeutics, Inc. (IOVA): Free Stock Analysis Report
 
Merck & Co., Inc. (MRK): Free Stock Analysis Report
 
TG Therapeutics, Inc. (TGTX): Free Stock Analysis Report
 
AMNEAL PHARMACEUTICALS, INC. (AMRX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research